Oncolys BioPharma Inc.
Notice Regarding Publication of OBP-301 Tumor Lysis Virus Paper
The NR G Oncology report on the combination of OBP-301 with chemoradiation in esophageal cancer was published in an overseas journal. Safety showed no DLTs, clinically complete responses achieved in all 13 evaluable patients, 1-year survival rate 60%, discussions with domestic experts on future development plans. Impact on fiscal period is unknown.
Key Figures
- Clinical trial: NRG-GI007
- Patients evaluable for efficacy: 13
- Clinically complete response: 100% (of 13)
- Clinically complete response across all patients: 87%
- One-year survival rate: 60%
- Progression-free survival: 53%
AI要約
News overview
OncoRIS Biopharma announced that the results of the NRG-GI007 trial of OBP-301 in combination with chemoradiation for patients with esophageal cancer were published in an international journal. The trial was conducted from June 2020 to July 2024, enrolling 15 patients and administering OBP-301 per protocol. No DLTs were observed, safety was assessed for all patients, and treatment-related severe adverse events were mainly neutropenia and lymphopenia. Clinically complete response (clinical CR) was 100% among the 13 evaluable patients and 87% among all 15 patients. One-year survival rate was 60%, and progression-free survival was 53%.
Future plans and impact
Based on these results, the company plans to decide on future development directions for this treatment regimen in the esophageal cancer field in consultation with domestic specialists. TerMeilysin (OBP-301) is already approved in Japan as a regenerative medicine product for radiation-combined treatment of esophageal cancer. It is stated that there will be no impact on the financial results for the fiscal year ending December 2026.
OncoRIS Biopharma, Inc.
Company overview · Stock price · Financial data · All IR
